Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

32.17
-0.6600-2.01%
Post-market: 31.74-0.4300-1.34%19:59 EDT
Volume:277.63K
Turnover:8.94M
Market Cap:1.54B
PE:-10.54
High:34.48
Open:33.33
Low:31.77
Close:32.83
52wk High:52.93
52wk Low:23.75
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.50
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:3.65
PE(LYR):-11.24

Loading ...

Rapport Therapeutics price target raised to $75 from $68 at Raymond James

TIPRANKS
·
Aug 17

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Rapport Therapeutics CEO Abraham Ceesay Sells 51,499 Shares Worth $2.41 Million

Reuters
·
Aug 13

Rapport Therapeutics Price Target Raised to $66.00/Share from $40.00 by HC Wainwright & Co.

Dow Jones
·
Aug 13

Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data

TIPRANKS
·
Aug 13

Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA)

TIPRANKS
·
Aug 06

Truist Financial Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Aug 06

Rapport Therapeutics Price Target Maintained with a $65.00/Share by BTIG

Dow Jones
·
Aug 06

Rapport Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Benzinga Earnings
·
Aug 05

Rapport Therapeutics Q2 FY26 Net Loss Widens to $56.6 Million; R&D Expense More than Doubled to $51.4 Million

Reuters
·
Aug 05

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

THOMSON REUTERS
·
Aug 05

Rapport Therapeutics CEO Abraham Ceesay Sells 2,210 Shares Worth $92,999.37

Reuters
·
Jul 30

William Blair Initiates Rapport Therapeutics at Outperform

MT Newswires Live
·
Jul 28

Rapport Therapeutics initiated with an Outperform at William Blair

TIPRANKS
·
Jul 28

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (CAMP), Fiserv (FISV) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 28

Goldman Sachs Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 22

Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF)

TIPRANKS
·
Jul 18

Rapport Therapeutics Price Target Maintained with a $65.00/share by BTIG

Dow Jones
·
Jul 16

Rapport Therapeutics CEO Abraham Ceesay Sells 8,210 Common Shares Worth $328,018

Reuters
·
Jul 16